| Name | Title | Contact Details |
|---|
We`re Villa Healthcare, and we make people better. Of course, we`re focused on quality care and good outcomes. But we`re here to do so much more. At Villa, we offer the very best in post-acute and long-term care. Our focus is providing exceptional clinical services by people who truly care, in an environment that promotes healing and wellness. Villa`s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We`ve always wanted to be a part of something greater, and we`ve made that a reality by both making people better and by creating and sharing opportunities. We currently have 22 facilities in four different states*. As Villa has grown, we have redoubled our efforts to ensure that the Villa experience is the same at every location. By extensively renovating our centers and hiring the best people we can, we are making our mark in the world of healthcare. It`s how Villa makes people better.
OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico, OncoHealth offers digital solutions for treatment review, real-world evidence, and virtual care across all cancer types.
Rapid Enrollment Solutions is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cameron Hall Assisted Living is a Canton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.